Company Encyclopedia
View More
name
CONBA
600572.SH
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nutritional supplements, hygiene products, healthy daily chemicals and food, and other self-care products; and processes agricultural products.
3.157 T
600572.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking29/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.03%B
    • Profit Margin10.46%B
    • Gross Margin54.51%B
  • Growth ScoreC
    • Revenue YoY1.80%C
    • Net Profit YoY41.33%B
    • Total Assets YoY3.94%C
    • Net Assets YoY6.02%B
  • Cash ScoreC
    • Cash Flow Margin956.07%B
    • OCF YoY1.80%C
  • Operating ScoreB
    • Turnover0.66B
  • Debt ScoreB
    • Gearing Ratio29.33%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CONBA released its performance for the first three quarters, with a net profit attributable to shareholders of 584 million yuan, a year-on-year increase of 12.65%

    According to the Zhitong Finance APP, CONBA disclosed its third-quarter report for 2025, stating that the company's revenue for the first three quarters reached 4.976 billion yuan, a year-on-year increase of 1.27%; net profit attributable to the parent company was 584 million yuan, a year-on-year increase of 12.65%; net profit excluding non-recurring items was 431 million yuan, a year-on-year increase of 1.61%; basic earnings per share were 0.232 yuan

    Zhitong·
    SH
    600572
    -0.21%
    Zhitong·
    SH
    600572
    -0.21%

    CONBA: Adenosylcobalamin capsules are expected to win the bid for the 11th batch of national centralized drug procurement

    CONBA announced that its wholly-owned subsidiary Hangzhou CONBA Pharmaceutical Co., Ltd. participated in the national 11th batch of centralized drug procurement, with adenosylcobalamin capsules expected to win the bid at a price of 3.81 yuan/box, supplying 8.3224 million capsules to provinces such as Sichuan, Hubei, and Ningxia. The procurement period is 3 years, with an agreed procurement volume of 2.62 million capsules. Winning the bid will promote product sales and market expansion, positively impacting the company's future operating performance

    Zhitong·
    SH
    600572
    -0.21%
    Zhitong·
    SH
    600572
    -0.21%

    CONBA Pharmaceutical Q3 Net Profit Up 69.1% Y/Y

    Zhejiang CONBA Pharmaceutical Co Ltd :Q3 NET PROFIT UP 69.1% Y/Y

    Reuters·
    SH
    600572
    -0.21%
    Reuters·
    SH
    600572
    -0.21%

    CONBA: Shen Qi resigns from the position of Vice President of the company

    On October 17th, CONBA announced that the company's board of directors received a written resignation letter from Vice President Shen Qi, who applied to resign from the position due to work adjustments. After resigning as Vice President, Shen Qi will no longer serve as the company's Chief Investment Officer but will continue to hold the position of Chairman of the Board at the company's holding subsidiary, Zhejiang Chinese Medical University Traditional Chinese Medicine Decoction Pieces Co., Ltd. Shen Qi's resignation will take effect upon the board's receipt of the resignation letter

    Zhitong·
    SH
    600572
    -0.21%
    Zhitong·
    SH
    600572
    -0.21%

    CONBA: Ultra-short-term financing bonds and medium-term notes approved for registration

    According to the Zhitong Finance APP, CONBA announced that the company recently received the "Acceptance of Registration Notice" issued by the National Association of Financial Market Institutional Investors (Zhong Shi Xie Zhu [2025] SCP252) and (Zhong Shi Xie Zhu [2025] MTN850). The association agreed to accept the company's registration of ultra-short-term financing bonds and medium-term notes. The registered amount for the company's ultra-short-term financing bonds is 1 billion yuan, and the registered amount for the medium-term notes is 1 billion yuan

    Zhitong·
    SH
    600572
    -0.21%
    Zhitong·
    SH
    600572
    -0.21%
    © 2025 Longbridge｜Disclaimer